TIDES Express | Qilu Pharmaceutical's Small Nucleic Acid Platform Achieves Breakthrough with GalNAc-conjugated siRNA Drug QLS7320 Granted IND Approval

Apr 24, 2026 09:07 CST Updated 09:07

Qilu Pharmaceutical

Specialty Formulations and Active Pharmaceutical Ingredients (API) Developer

｜Edited by the Content Team of Zhong肽 Biochemical

2026YearApril22Day，QLS7320 Injection, a Class 1 innovative drug independently developed by Qilu Pharmaceutical Co., Ltd., has received clinical trial approval from the Center for Drug Evaluation (CDE) of China's National Medical Products Administration (NMPA) for the first time and will soon commence clinical trials in China.Paroxysmal Nocturnal Hemoglobinuria(Clinical research on PNH). This complement-targeted drug, with a novel mechanism of action, is expected to bring cutting-edge treatment options to patients.

QLS7320 Injection is an siRNA drug that achieves liver-targeted delivery through conjugation with GalNAc (N-acetylgalactosamine). Its successful advancement into the clinical trial stage marks another solid step forward for Qilu Pharmaceutical in the field of small nucleic acid drug research and development. This not only demonstrates the increasingly mature technical system of the platform but also further highlights the company’s scientific research capabilities in new drug creation. As a key innovative platform of Qilu Pharmaceutical, the small nucleic acid drug research and development platform will continue to advance cutting-edge exploration, bringing more globally competitive innovative therapies to patients in the future.

Approved for clinical use this timePNHIndications: It is a rare acquired hemolytic disease driven by abnormal activation of the complement system, characterized by intravascular hemolysis, thrombotic events, and bone marrow failure, which can be life-threatening. Some patients respond poorly to existing treatments. Targeting the complement pathway is considered one of the fundamental strategies for treating these diseases. However, innovative therapies in this field are still relatively scarce in China.

Source:

1.Qilu Pharmaceutical